Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A review.

Literature DB >> 26155387

Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A review.

Sandeep Nayar¹, Prokar Dasgupta¹, Christine Galustian¹.

Abstract

Cells used in adoptive cell-transfer immunotherapies against cancer include dendritic cells (DCs), natural-killer cells, and CD8+ T-cells. These cells may have limited efficacy due to their lifespan, activity, and immunosuppressive effects of tumor cells. Therefore, increasing longevity and activity of these cells may boost their efficacy. Four cytokines that can extend immune effector-cell longevity are IL-2, IL-7, IL-21, and IL-15. This review will discuss current knowledge on effector-cell lifespans and the mechanisms by which IL-2, IL-7, IL-15, and IL-21 can extend effector-cell longevity. We will also discuss how lifespan and efficacy of these cells can be regulated to allow optimal clinical benefits.

Entities: Chemical

Keywords: Adoptive transfer; Dendritic cells; NK cells; T cells; cytokines; lifespan

Year: 2015 PMID： 26155387 PMCID： PMC4489929 DOI： 10.1080/2162402X.2014.1002720

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

139 in total

1. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors: C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal: Proc Natl Acad Sci U S A Date: 2002-11-11 Impact factor: 11.205

2. Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy.

Authors: Betty Li; Melinda J VanRoey; Karin Jooss
Journal: Clin Immunol Date: 2007-02-22 Impact factor: 3.969

Review 3. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma.

Authors: Mehmood H Hashmi; Peter J Van Veldhuizen
Journal: Expert Opin Biol Ther Date: 2010-05 Impact factor: 4.388

Review 4. The role of interleukin-2 during homeostasis and activation of the immune system.

Authors: Onur Boyman; Jonathan Sprent
Journal: Nat Rev Immunol Date: 2012-02-17 Impact factor: 53.106

Review 5. Interleukin-15 biology and its therapeutic implications in cancer.

Authors: Jason C Steel; Thomas A Waldmann; John C Morris
Journal: Trends Pharmacol Sci Date: 2011-10-25 Impact factor: 14.819

6. Inhibition of gamma delta T cell development and early thymocyte maturation in IL-7 -/- mice.

Authors: T A Moore; U von Freeden-Jeffry; R Murray; A Zlotnik
Journal: J Immunol Date: 1996-09-15 Impact factor: 5.422

7. Cytokines IL-1 alpha, IL-6, and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression: restoration by interferon gamma.

Authors: Giovana R Thomas; Zhong Chen; Elena Leukinova; Carter Van Waes; Judy Wen
Journal: Cancer Immunol Immunother Date: 2003-10-09 Impact factor: 6.968

8. Immune responses in interleukin-2-deficient mice.

Authors: T M Kündig; H Schorle; M F Bachmann; H Hengartner; R M Zinkernagel; I Horak
Journal: Science Date: 1993-11-12 Impact factor: 47.728

9. Cytokine requirements for the growth and development of mouse NK cells in vitro.

Authors: Jennifer A Toomey; Frances Gays; Don Foster; Colin G Brooks
Journal: J Leukoc Biol Date: 2003-08 Impact factor: 4.962

10. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors: Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal: J Exp Med Date: 2005-10-03 Impact factor: 14.307

14 in total

1. Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma.

Authors: Markus Granzin; Ana Stojanovic; Matthias Miller; Richard Childs; Volker Huppert; Adelheid Cerwenka
Journal: Oncoimmunology Date: 2016-08-05 Impact factor: 8.110

2. Injectable, Tough Alginate Cryogels as Cancer Vaccines.

Authors: Ting-Yu Shih; Serena O Blacklow; Aileen W Li; Benjamin R Freedman; Sidi Bencherif; Sandeep T Koshy; Max C Darnell; David J Mooney
Journal: Adv Healthc Mater Date: 2018-02-14 Impact factor: 9.933

3. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.

Authors: Cesar Sommer; Bijan Boldajipour; Tracy C Kuo; Trevor Bentley; Janette Sutton; Amy Chen; Tao Geng; Holly Dong; Roman Galetto; Julien Valton; Thomas Pertel; Alexandre Juillerat; Annabelle Gariboldi; Edward Pascua; Colleen Brown; Sherman M Chin; Tao Sai; Yajin Ni; Philippe Duchateau; Julianne Smith; Arvind Rajpal; Thomas Van Blarcom; Javier Chaparro-Riggers; Barbra J Sasu
Journal: Mol Ther Date: 2019-04-08 Impact factor: 11.454

Review 10. Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence.

Authors: Sean J Judge; William J Murphy; Robert J Canter
Journal: Front Cell Infect Microbiol Date: 2020-02-13 Impact factor: 5.293